Phase II, Open Label Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Ascorbic acid (Primary) ; Erlotinib; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Aug 2018 Biomarkers information updated
- 25 Jun 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
- 20 Mar 2012 New trial record